Welcome to Seeking Alpha's Wall Street Lunch, our afternoon update on today's market action, news, and analysis.

Good afternoon. Today is Thursday, April 17th, and I'm your host, Kim Kong. Our top story so far.

Eli Lilly is rallying after the company said its oral GLP1 receptor agonist or four glopron reached

the main goal in a phase three trial for adults with type 2 diabetes.

Citing top line data from its Achieve 1 clinical trial for a key secondary endpoint, Lilly said

that the once daily pill reduced weight by about 8% on average, 16 pounds, at the highest dose in the 40-week trial.

Lilly's main rival in the weight loss drug market, Novo Nordisk, and other obesity drug

developers, such as Viking Therapeutics and Amgen, are seeing pressure on shares.

Lilly's CEO, David Rick, said, as a convenient once-daily pill or for glapron may provide

a new option, and, if approved,

could be readily manufactured and launched at scale for use by people around the world.

The global trial involved 559 patients with type 2 diabetes, who had inadequate glycemic control

from diet and exercise alone. In Achieve one's main goal, or four glopron lowered a key diabetes biomarker called

A1C by 1.3 to 1.6% from a baseline of 8% across 3 milligram, 12 milligram, and 36 milligram doses

in the per-proticle study population, while those on placebo witnessed 0.1% of A1C reduction.

Going the other way is Dow Component United Health,

which is sinking after it slashed its full-year outlook

following lower-than-expected Q1 results.

The company revised its 2025-adjusted EPS Outlook

to 26-50, down from 2950 to 30 in its forecast in December, and below the 2974 consensus.

CEO Andrew Whitty said, United Health Group grew to serve more people more comprehensively, but did not perform up to our expectations.

We are aggressively addressing those challenges to position us well for the years ahead and return to our long-term earnings growth rate target of 13 to 16%.

...